Cargando…

Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible

BACKGROUND: Despite the widespread use of amoxicillin in young children, efforts to establish the feasibility of simplified dosing regimens in resource-limited settings have relied upon empirical evidence of efficacy. Given the antibacterial profile of beta-lactams, understanding of the determinants...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Agate, Salvatore, Musuamba, Flora Tshinanu, Della Pasqua, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549385/
https://www.ncbi.nlm.nih.gov/pubmed/33117151
http://dx.doi.org/10.3389/fphar.2020.521933
_version_ 1783592784036364288
author D’Agate, Salvatore
Musuamba, Flora Tshinanu
Della Pasqua, Oscar
author_facet D’Agate, Salvatore
Musuamba, Flora Tshinanu
Della Pasqua, Oscar
author_sort D’Agate, Salvatore
collection PubMed
description BACKGROUND: Despite the widespread use of amoxicillin in young children, efforts to establish the feasibility of simplified dosing regimens in resource-limited settings have relied upon empirical evidence of efficacy. Given the antibacterial profile of beta-lactams, understanding of the determinants of pharmacokinetic variability may provide a more robust guidance for the selection of a suitable regimen. Here we propose a simplified dosing regimen based on pharmacokinetic-pharmacodynamic principles, taking into account the impact of growth, renal maturation and disease processes on the systemic exposure to amoxicillin. MATERIALS AND METHODS: A meta-analytical modeling approach was applied to allow the adaptation of an existing pharmacokinetic model for amoxicillin in critically ill adults. Model parameterization was based on allometric concepts, including a maturation function. Clinical trial simulations were then performed to characterize exposure, as defined by secondary pharmacokinetic parameters (AUC, C(max), C(min)) and T>MIC. The maximization of the T>MIC was used as criterion for the purpose of this analysis and results compared to current WHO guidelines. RESULTS: A two-compartment model with first order absorption and elimination was found to best describe the pharmacokinetics of amoxicillin in the target population. In addition to the changes in clearance and volume distribution associated with demographic covariates, our results show that sepsis alters drug distribution, leading to lower amoxicillin levels and longer half-life as compared to non-systemic disease conditions. In contrast to the current WHO guidelines, our analysis reveals that amoxicillin can be used as a fixed dose regimen including two weight bands: 125 mg b.i.d. for patients with body weight < 4.0 kg and 250 mg b.i.d. for patients with body weight ≥ 4.0 kg. CONCLUSIONS: In addition to the effect of developmental growth and renal maturation, sepsis also alters drug disposition. The use of a model-based approach enabled the integration of these factors when defining the dose rationale for amoxicillin. A simplified weight-banded dosing regimen should be considered for neonates and young infants with sepsis when referral is not possible.
format Online
Article
Text
id pubmed-7549385
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75493852020-10-27 Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible D’Agate, Salvatore Musuamba, Flora Tshinanu Della Pasqua, Oscar Front Pharmacol Pharmacology BACKGROUND: Despite the widespread use of amoxicillin in young children, efforts to establish the feasibility of simplified dosing regimens in resource-limited settings have relied upon empirical evidence of efficacy. Given the antibacterial profile of beta-lactams, understanding of the determinants of pharmacokinetic variability may provide a more robust guidance for the selection of a suitable regimen. Here we propose a simplified dosing regimen based on pharmacokinetic-pharmacodynamic principles, taking into account the impact of growth, renal maturation and disease processes on the systemic exposure to amoxicillin. MATERIALS AND METHODS: A meta-analytical modeling approach was applied to allow the adaptation of an existing pharmacokinetic model for amoxicillin in critically ill adults. Model parameterization was based on allometric concepts, including a maturation function. Clinical trial simulations were then performed to characterize exposure, as defined by secondary pharmacokinetic parameters (AUC, C(max), C(min)) and T>MIC. The maximization of the T>MIC was used as criterion for the purpose of this analysis and results compared to current WHO guidelines. RESULTS: A two-compartment model with first order absorption and elimination was found to best describe the pharmacokinetics of amoxicillin in the target population. In addition to the changes in clearance and volume distribution associated with demographic covariates, our results show that sepsis alters drug distribution, leading to lower amoxicillin levels and longer half-life as compared to non-systemic disease conditions. In contrast to the current WHO guidelines, our analysis reveals that amoxicillin can be used as a fixed dose regimen including two weight bands: 125 mg b.i.d. for patients with body weight < 4.0 kg and 250 mg b.i.d. for patients with body weight ≥ 4.0 kg. CONCLUSIONS: In addition to the effect of developmental growth and renal maturation, sepsis also alters drug disposition. The use of a model-based approach enabled the integration of these factors when defining the dose rationale for amoxicillin. A simplified weight-banded dosing regimen should be considered for neonates and young infants with sepsis when referral is not possible. Frontiers Media S.A. 2020-09-25 /pmc/articles/PMC7549385/ /pubmed/33117151 http://dx.doi.org/10.3389/fphar.2020.521933 Text en Copyright © 2020 D’Agate, Musuamba and Della Pasqua http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
D’Agate, Salvatore
Musuamba, Flora Tshinanu
Della Pasqua, Oscar
Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible
title Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible
title_full Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible
title_fullStr Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible
title_full_unstemmed Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible
title_short Dose Rationale for Amoxicillin in Neonatal Sepsis When Referral Is Not Possible
title_sort dose rationale for amoxicillin in neonatal sepsis when referral is not possible
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549385/
https://www.ncbi.nlm.nih.gov/pubmed/33117151
http://dx.doi.org/10.3389/fphar.2020.521933
work_keys_str_mv AT dagatesalvatore doserationaleforamoxicillininneonatalsepsiswhenreferralisnotpossible
AT musuambafloratshinanu doserationaleforamoxicillininneonatalsepsiswhenreferralisnotpossible
AT dellapasquaoscar doserationaleforamoxicillininneonatalsepsiswhenreferralisnotpossible